Glenmark Q1 net profit up 3% to Rs191 crore
Total income rises 13.6% from `1457 crore to `1655 crore30-07-2015
30-07-2015
Announces Q1 results, Limited Review Report, Results Press Release & Management Discussion and Analysis for the Quarter ended June 30, 2015
Glenmark Pharmaceuticals Ltd has announced the following results for the quarter ended June 30, 2015:The Unaudited Standalone results for the Quarter ended June 30, 2015"The Company has posted a net profit of Rs. 3352.02 million for the quarter ended June 30, 2015 where as the same was at Rs. 1039.34 million for the quarter ended June 30, 2014. Total Income is Rs. 12738.53 million for the quarter ended June 30, 2015 where as the same...30-07-2015
Clarifies on News Item
With reference to the news article in Financial Express July 29, 2015 captioned "Glenmark Pharma's skin gel infringes patent, says US court", Glenmark Pharmaceuticals Ltd has Clarified to BSE as under :"We confirm the decision has been passed by the U.S.Court. Challenges in Para-IV filings are a usual practice in U.S. and the said decision can be appealed against....29-07-2015
Clarification sought from Glenmark Pharmaceuticals Ltd
The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with reference to the news article in Financial Express July 29, 2015 captioned "Glenmark Pharma's skin gel infringes patent, says US court" The reply is awaited.29-07-2015
US court rejects Glenmarks patent plea, stock down 3%
A US court ruled against Glenmark in a patent litigation over skin care drug28-07-2015
Glenmark to focus on Indian product launches
5-6 products to be launched for the Indian market over the next two years to boost sales and beat the industry growth rate24-07-2015
Q1 results on July 30, 2015
Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 30, 2015 to consider and approve the Company's Unaudited Financial Statements for the First Quarter ended June 30, 2015 (Q1).Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window closed for Directors and other designated employees of the Company on June 23, 2015 and...20-07-2015
Outcome of Operations Committee Meeting
Glenmark Pharmaceuticals Ltd has informed BSE that the Operations Committee of the Board of Directors of the Company, at its Meeting held on June 22, 2015 allotted 32,500 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.22-06-2015
Outcome of Operations Committee Meeting
Glenmark Pharmaceuticals Ltd has informed BSE that the Operations Committee of the Board of Directors of the Company, at its Meeting held on June 16, 2015, allotted 17,803 Equity Shares of the face value of Re. 1/- each in the ratio of Four (4) Equity Shares of Re. 1 each of Glenmark Pharmaceuticals Limited for every Five (5) Equity Shares of Rs. 10/- each held of Glenmark Generics Limited pursuant to Scheme of Amalgamation of Glenmark Generics Limited...16-06-2015
Glenmark Pharmaceuticals receives ANDA approval for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated June 15, 2015 titled "Glenmark Pharmaceuticals receives ANDA approval for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg".15-06-2015